This ADC product is comprised of an anti-DLL4 monoclonal antibody conjugated via a MC-Vc-PAB linker to SN38. The SN-38 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell,
* VAT and and shipping costs not included. Errors and price changes excepted